Treatment of multiple myeloma in patients refractory to daratumumab/anti-CD38 monoclonal antibodies: A systematic review

BCMA-directed therapies, including CAR-T cell therapy and bispecific antibodies, show promising efficacy in patients with multiple myeloma refractory to daratumumab. These treatments demonstrate high response rates and improved survival outcomes. Further research is needed to establish best practices in this setting.